Suppr超能文献

急性肝衰竭的病因及预后:对单中心治疗的50例患者的回顾性分析。

Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center.

作者信息

Hiramatsu Akira, Takahashi Shoichi, Aikata Hiroshi, Azakami Takahiro, Katamura Yoshio, Kawaoka Tomokazu, Uka Kiminori, Yamashina Keitaro, Takaki Shintaro, Kodama Hideaki, Jeong Soo Cheol, Imamura Michio, Kawakami Yoshiiku, Chayama Kazuaki

机构信息

Department of Medicine and Molecular Science, Hiroshima University, Hiroshima, Japan.

出版信息

J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1216-22. doi: 10.1111/j.1440-1746.2008.05402.x. Epub 2008 Jul 10.

Abstract

BACKGROUND AND AIM

Acute liver failure (ALF) remains a devastating disease carrying considerable mortality. Since deceased donor liver transplantation is rarely performed in Japan, the artificial liver support system (ALS) and living donor liver transplantation (LDLT) are the main modalities used for treatment of ALF. The aim of this study was to analyze the outcome of ALF patients and to evaluate therapies for ALF according to etiology.

METHODS

Fifty consecutive patients with ALF were treated between January 1990 and December 2006. Prior to 1997, patients received ALS only. After 1997, ALS and/or LDLT were applied. LDLT was performed in 10 patients.

RESULTS

Four of 15 (27%) pre-1997 ALF patients survived, and 16 of 35 (46%) post-1997 ALF patients survived, including eight who underwent LDLT. The causes of ALF were acute hepatitis B virus (HBV) infection in 18%, severe acute exacerbation (SAE) of chronic HBV infection in 18%, autoimmune hepatitis (AIH) in 8%, and cryptogenic hepatitis in 44%. In total, 67% of the patients with ALF caused by acute HBV infection and AIH were cured without LDLT; only 11% of patients with ALF caused by SAE of HBV and 24% of cryptogenic hepatitis were successfully treated without LDLT. Notably, 80% of patients with cryptogenic hepatitis who underwent LDLT survived.

CONCLUSION

Since 1997, the survival rate of ALF patients has increased, mainly due to the introduction of LDLT. Liver transplantation should be performed especially in patients with ALF caused by SAE of HBV and cryptogenic hepatitis.

摘要

背景与目的

急性肝衰竭(ALF)仍然是一种死亡率很高的灾难性疾病。由于在日本很少进行尸体供肝肝移植,人工肝支持系统(ALS)和活体供肝肝移植(LDLT)是治疗ALF的主要方式。本研究的目的是分析ALF患者的治疗结果,并根据病因评估ALF的治疗方法。

方法

1990年1月至2006年12月期间,连续治疗了50例ALF患者。1997年之前,患者仅接受ALS治疗。1997年之后,应用了ALS和/或LDLT。10例患者接受了LDLT。

结果

1997年前的15例ALF患者中有4例(27%)存活,1997年后的35例ALF患者中有16例(46%)存活,其中8例接受了LDLT。ALF的病因包括18%为急性乙型肝炎病毒(HBV)感染,18%为慢性HBV感染的严重急性加重(SAE),8%为自身免疫性肝炎(AIH),44%为隐源性肝炎。总体而言,由急性HBV感染和AIH引起的ALF患者中有67%未经LDLT治愈;由HBV的SAE引起的ALF患者中只有11%以及隐源性肝炎患者中24%未经LDLT成功治疗。值得注意的是,接受LDLT的隐源性肝炎患者中有80%存活。

结论

自1997年以来,ALF患者的生存率有所提高,主要是由于引入了LDLT。对于由HBV的SAE和隐源性肝炎引起的ALF患者,尤其应进行肝移植。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验